Treatment News : Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 14, 2014

Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV

by Benjamin Ryan

Soy sauce has become the latest supermarket item to contain the answer to HIV, according to a savory smorgasbord of reporting in the popular press. But don’t go downing bottles of the brine just yet, because there’s a small problem: The HIV-fighting molecule in question is not actually known to be in soy sauce at all, it is only “related to flavor enhancers found in soy sauce,” according to the press release from the University of Missouri School of Medicine that spawned the media reports.

The tall tale began in 2001 when the Japanese soy sauce manufacturer Yamasa, while searching for a flavor enhancer for the popular condiment, synthesized a molecule known as EFdA, which belongs to a family of compounds called nucleoside analogues. Eventually, laboratory research found that EFdA is a nucleoside reverse transcriptase inhibitor (NRTI), which is a class of HIV-fighting drugs included under the nucleoside analogue umbrella. Not only that, but the molecule is highly effective at fighting HIV.

In a prime example of how the popular press tripped up on the finer details of this story, the LA Weekly, which lifted most of its article verbatim from the university press release, claimed, “A compound found in soy sauce may be more potent than the current top antiviral therapy in fighting HIV…. Seventy times stronger, in fact.”

Not quite. The molecule’s strengths are particularly notable when compared with those of the popular HIV drug Viread (tenofovir). For starters, EFdA is at least 10 times more potent at combatting “wild-type” (non-drug resistant) virus than Viread. And when HIV that has been exposed to Viread develops a particular resistance mutation called K65R, EFdA is 70 times more effective than Viread at fighting the Viread-resistant virus. (Thus, issuing a blanket statement about the molecule being perhaps 70 times stronger than other antiretrovirals is misleading; highly specific context is required.) In other words, the K65R mutation causes HIV to become hypersusceptible to EFdA, making the molecule even more effective as an antiretroviral to combat Viread-resistant virus than to fight wild-type.

Sarra S. Herzog, a spokesperson for Merck, which licensed EFdA from Yamasa two years ago, said she could not discuss the molecule’s development at this time, except to say that it is not in Phase II trials.

As for the widespread claims in the press that soy sauce itself contains an HIV-fighting component, the phenomenon appears to have stemmed from the University of Missouri press release, which initially had a headline claiming, “Soy sauce molecule may unlock drug therapy for HIV patients.” (After POZ alerted the university to the error, the headline was corrected.) Stefan Sarafianos, PhD, an associate professor of molecular microbiology and immunology and biochemistry at the University of Missouri School of Medicine, said in an email to POZ/AIDSMeds that he bears “some responsibility for the misunderstanding in the press,” because in editing the press release he overlooked the faulty headline.

The initial draft of the press release also stated that EFdA is 70 times more potent than Viread, but left out the important fact that this is in the context of Viread-resistant virus. This perhaps explains the LA Weekly’s snafu on this point.

Sarafianos still stressed in his email that “EFdA is a very promising molecule.” And in the press release he stated the molecule “is less likely to cause resistance in HIV patients because it is more readily activated and is less quickly broken down by the body as similar existing drugs.”

As for the award for the most creative headline in the press? It goes to Tech Times, which touted: “Soy sauce may hold answer to HIV cure. You heard that right.”

To read the University of Missouri press release, click here.

To read the LA Weekly story, click here.

To read the Tech Times story, click here.

To read a longer article on EFdA from the University of Missouri, click here.

To read a 2013 paper in Retrovirology on EFdA’s hypersensitivity to Viread-resistant HIV, click here.

Editor's note: a previous vesion of this article indicated that the K65R mutation causes EFdA to become hypersensitive to HIV, whereas the correct characterization is that this mutation causes the virus to become hypersusceptible to EFdA.

Search: Soy sauce, HIV, cure, EFdA, nucleoside analogue, nucleoside reverse transcriptase inhibitor, NRTI, LA Weekly, erroneous reporting, University of Missouri, K65R mutation, Viread, tenofovir, Stefan Sarafianos, Tech Times.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (7 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    slimcuteguy
    Asheville
    North Carolina


    OahuAJ
    Turlock
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.